Intercellular adhesion molecule 1 is a sensitive and diagnostically useful immunohistochemical marker of papillary thyroid cancer (PTC) and of PTC-like nuclear alterations in Hashimoto's thyroiditis

Abstract

Intercellular adhesion molecule 1 (ICAM-1) is important in the progression of inflammatory responses. Recently, increased levels of ICAM-1 have been reported in a number of types of malignancy. The present study aimed to investigate ICAM-1 expression in papillary thyroid cancer (PTC) and in Hashimoto's thyroiditis (HT) with PTC-like nuclear alterations, and to assess the predictive value of ICAM-1 in thyroid lesions. ICAM-1 expression was retrospectively investigated in 132 consecutive cases of PTC, 72 cases of HT, 10 of follicular cancer, 15 of follicular adenoma, 16 of nodular goiter and 8 samples of normal thyroid tissue using immunohistochemical analyses, and in 42 PTC patients using western blotting. ICAM-1 expression was not detected in normal follicular cells, follicular lesions (adenoma and cancer) and benign nodular hyperplasia, but was frequently overexpressed in PTC cells. ICAM-1 overexpression was associated with extra-thyroidal invasion and lymph node metastasis; no association was found with age, gender, tumor size, multifocality, pathological stage, recurrence or distant metastasis. ICAM-1 expression in HT patients with PTC-like nuclear alterations was significantly higher than that in HT cases with non-PTC-like features. Compared with antibodies against cytokeratin 19, galectin-3 and Hector Battifora mesothelial-1, ICAM-1 was the most sensitive marker for the detection of PTC-like features in HT. These findings demonstrate that ICAM-1 expression is upregulated in PTC and in HT with PTC-like nuclear alterations. This feature may be an important factor in the progression of cancer of the thyroid gland.

Metadichol® A Novel Inverse Agonist of Thyroid Receptor and its Applications in Thyroid Diseases

“…This feature may be an important factor in the progression of cancer of the thyroid gland. Similar work was reported by Zhang et al that ICAM1 expression is upregulated in PTC (Papillary Thyroid Cancer) and in HT (Hashimoto's disease) [10]. Buitrago et al showed that ICAM1 was upregulated in PTC at the levels of both gene and protein expression.…”

CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors

“…Previous reports have demonstrated a positive correlation between ICAM-1 RNA and protein expression levels and the aggressive potential of PTC (25, 26), constituting ICAM-1 as a biomarker and a potential target for therapeutic interventions in thyroid cancer. PTCs are most commonly driven by two mutually exclusive somatic mutations, BRAF V600E or mutated RAS (29).…”

“…Moreover, clinical trials support the safety and tolerability of targeting ICAM-1 using monoclonal antibodies (20–24). Previous studies have shown that ICAM-1 expression is highly correlated with both the malignancy and metastatic status of thyroid tumors, as well as the V600E BRAF (BRAF V600E ) mutation (25, 26). The stark correlation between ICAM-1 expression and adverse prognostic outcomes in thyroid cancer patients suggests that ICAM-1 may serve as a therapeutic target for advanced, recurrent thyroid tumors.…”

Gene Expression Patterns Unveil New Insights in Papillary Thyroid Cancer

“…A previous profiling study revealed similar altered mechanisms, where overexpressed genes were related mainly to cell adhesion processes, protease binding, or ECM-receptor interactions [25]. ICAM-1 (Intercellular adhesion molecule 1) is an important molecule that has an important role in cell adhesion regulation and in the inflammatory response progression [26]. It was previously proven that ICAM-1 is upregulated in both classical and tall-cell PTC, therefore it could be considered a biomarker of PTC progression [26].…”

“…ICAM-1 (Intercellular adhesion molecule 1) is an important molecule that has an important role in cell adhesion regulation and in the inflammatory response progression [26]. It was previously proven that ICAM-1 is upregulated in both classical and tall-cell PTC, therefore it could be considered a biomarker of PTC progression [26].…”